Class action lawsuits against dietary supplement and functional food companies continue to increase and present a significant legal risk to these industries. In the past, class actions tended to target egregious and outlandish claims, but more and more, many of these cases are challenging basic structure/function claims. Given this landscape, it is important for companies […]
As FDA continues to contemplate potential regulatory pathways for hemp-derived CBD, an increasing number of states are moving forward with their own laws and policies aimed at regulating this popular product category, especially in the dietary supplement and food space. Several states are imposing robust testing, labeling and registration requirements for these products—with more likely […]
The Federal Trade Commission will have to be more precise when issuing guidance documents, won’t be able to use them to circumvent the rulemaking process and can’t ask judges to defer to the guidance when issuing decisions. These changes are a result of an executive order signed by President Donald Trump Oct. 9 as part of his administration’s […]
While targeting claims that CBD treats serious diseases like cancer, the Federal Trade Commission has issued a few rounds of warning letters—including three this month. But in an interview with Natural Products INSIDER, an FTC official suggested the agency will take more forceful enforcement action in the future against marketers who advertise CBD as a […]
Leading regulatory and intellectual property law firm Amin Talati today announced that effective June 1, 2019, the firm’s name changed to Amin Talati Wasserman LLP, making Ivan Wasserman, who also serves as the firm’s managing partner, a name partner. “Our new name is a reflection of how far we have come and how far we […]
Neil O’Flaherty has over 28 years of experience involving FDA regulation of medical devices and other products. He has spoken, written and advised extensively on medical device and other FDA-related topics, including the regulation of mobile medical apps and other medical software products, in vitro diagnostics (including genetic and other laboratory tests), human cells, tissues, and […]
New Hope Network recently featured an article published by Katie Bond titled, “How to Back Up Advertising Claims and Avoid Risk”. Katie discusses the recent regulatory landscape with respect to advertising law and provides valuable insight into strategies for mitigating risk. To read the full article, please click HERE.
Law360 recently named the Federal Circuit’s July ruling in St. Regis Mohawk Tribe, et al. v. Mylan Pharmaceuticals Inc., et al., an appeal from the United States Patent Trial and Appeal Board, as one of the five Biggest Patent Cases of 2018. Amin Talati Upadhye LLP attorneys submitted Comments of Amici Curiae to the PTAB […]
Amin Talati Wasserman LLP announced today that Rend Al-Mondhiry has been elevated to Partner of the firm. Rend is one of the most well-known and respected attorneys serving the dietary supplement industry. Since joining the MORE >
The content in the Amin Talati Wasserman web site may constitute attorney advertising or advertising material within the meaning of applicable bar rules, and/or under the Rules of Professional Conduct governing lawyers. Nothing in this site is to be considered as either creating an attorney-client relationship between the reader and Amin Talati Wasserman or as the rendering of legal advice for any specific matter.